Use of Peripheral Blood DNA for Genotype Antiretroviral Resistance Testing in Drug-Naive HIV-Infected Subjects

Abstract

Parallel analysis of peripheral blood mononuclear cell DNA and plasma RNA from 169 drug-naive human immunodeficiency virus-infected subjects revealed that evaluation of both compartments increases the sensitivity of detection of drug resistance-related mutations, compared with examination of either source alone. Peripheral blood mononuclear cell DNA may play a role in the surveillance of transmitted antiretroviral resistance.

Comparing Peripheral Blood Mononuclear Cell DNA and Circulating Plasma viral RNA pol Genotypes of Subtype C HIV-1

“…Some studies have found that vRNA demonstrates more DRM compared to PBMC DNA [6,10,11]; some have found specific DRM in PBMC DNA that were not detected in vRNA [12–15] with questions regarding their clinical significance; and some studies have observed no significant difference in DRM between the two sources [16]. Most of these studies have suggested the use of PBMC DNA with vRNA sequencing to increase the sensitivity of drug resistance testing while two studies have suggested PBMC DNA as an alternate to vRNA at lower viral loads [6] or if plasma samples are not available [16].…”

Human immunodeficiency virus‐1 genotypic drug resistance among volunteer blood donors in Yunnan, China

“…Comparing cell-free and cell-associated virus in drug resistance testing might be useful to predict the emergence of future drug resistance and subsequent treatment failure, especially when plasma viral load remains subdued or below detection. [17][18][19] The utility of PBMNCs as drug-resistant samples has not been reported in China.…”

Prevalence of HIV type 1 drug resistance mutations in treatment-naïve and experienced patients from resource-limited settings with universal access to antiretroviral therapy: a survey in two small Brazilian cities

“…Since we wished to study all patients (regardless of treatment history), including those with PVL below detection limit, we chose to perform resistance testing by targeting HIV-1 DNA from the PBMC proviral compartment, instead of the most commonly used plasma HIV-1 RNA. Although studies have found that the detection of resistance mutations in the HIV-1 RNA plasma compartment may precede that in PBMC (Kaye et al 1995, Bi et al 2003, it has been shown that HIV DNA recovered from the proviral compartment can reliably be used in drug resistance genotyping (Devereux et al 2000, Sarmati et al 2003, Chew et al 2005, Parisi et al 2007, Vicenti et al 2007). In addition, proviral sequences can be useful to detect archived mutations that can compromise future therapeutic options, such as those selected by previously used regimens (Sarmati et al 2003, SG Parisi et al unpublished observations), and have been found to have greater sensitivity after treatment interruption in treatment experienced patients (Venturi et al 2002).…”